Akari Therapeutics PLC (NASDAQ:AKTX) shares rose 8.9% during trading on Thursday . The stock traded as high as $8.65 and last traded at $6.74. Approximately 229,444 shares traded hands during trading, a decline of 38% from the average daily volume of 367,823 shares. The stock had previously closed at $7.40.

AKTX has been the subject of several research reports. Canaccord Genuity reissued a “buy” rating and set a $15.00 price objective (down previously from $33.00) on shares of Akari Therapeutics PLC in a report on Monday, June 26th. Zacks Investment Research downgraded shares of Akari Therapeutics PLC from a “strong-buy” rating to a “hold” rating in a report on Monday, September 18th. William Blair reissued an “outperform” rating on shares of Akari Therapeutics PLC in a report on Tuesday, July 4th. Chardan Capital reissued a “neutral” rating and set a $2.50 price objective (down previously from $6.00) on shares of Akari Therapeutics PLC in a report on Friday, August 11th. Finally, ValuEngine raised shares of Akari Therapeutics PLC from a “strong sell” rating to a “sell” rating in a report on Monday, September 11th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $8.00.

The firm’s market cap is $80.55 million. The stock’s 50 day moving average is $5.40 and its 200 day moving average is $7.23.

An institutional investor recently bought a new position in Akari Therapeutics PLC stock. Hikari Power Ltd purchased a new position in shares of Akari Therapeutics PLC (NASDAQ:AKTX) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 60,012 shares of the biopharmaceutical company’s stock, valued at approximately $277,000. Hikari Power Ltd owned about 0.51% of Akari Therapeutics PLC at the end of the most recent quarter. 26.85% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: “Akari Therapeutics PLC (AKTX) Stock Price Up -8.9%” was first reported by Daily Political and is the property of of Daily Political. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The original version of this news story can be accessed at https://www.dailypolitical.com/2017/10/12/akari-therapeutics-plc-aktx-stock-price-up-8-9.html.

Akari Therapeutics PLC Company Profile

Akari Therapeutics, Plc, formerly Celsus Therapeutics Plc, is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome.

Receive News & Ratings for Akari Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.